WOCKPHARMA2018-04-012018-06-30in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2018-04-012018-06-30in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2018-04-012018-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2018-04-012018-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares WOCKPHARMA 2018-04-01 2019-03-31 2018-07-18 INR Crores First quarter Single segment Pharmaceuticals 2018-04-01 2018-06-30 Unaudited Standalone 5393600000.00 83300000.00 5476900000.00 1138300000.00 1288300000.00 -206500000.00 1366800000.00 379200000.00 274800000.00 1404800000.00 5645700000.00 -168800000.00 0.00 -168800000.00 0.00 -17700000.00 -17700000.00 0.00 -151100000.00 0.00 0.00 0.00 0.00 -151100000.00 2800000.00 -148300000.00 0.00 0.00 553200000.00 5 -1.37 -1.37 0.00 0.00 -1.37 -1.37 Notes to Standalone Resultstttttttttttttt n1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 04, 2018. The results have been subjected to limited review by the Statutory auditors of the Company. nttttttttt n2) During the quarter, the Company has allotted 8,200 Equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options.ttttttt ntttttttttt n3) Figures for the quarter ended March 31, 2018 are the balancing figures between the audited figures in respect of the full financial year and the reviewed figures upto the third quarter of the financial year 2017-18.tttttttttt n4) Effective April 01, 2018, the Company has adopted Ind AS 115: Revenue from Contracts with Customers that has become mandatorily applicable for reporting periods beginning on or after April 01, 2018 replacing the existing revenue recognition standard. In accordance with the first time adoption options available in the said standard, the Company has chosen the cumulative effect method and applied retrospectively only to contracts that are not completed as at the date of initial application (i.e. April 01, 2018). Accordingly, the comparatives have not been restated in line with the provisions of the standard. The adoption of the standard did not have any material impact to the financial statements of the Company for the three months ended June 30, 2018.ttttttttt n5) The Company is exclusively into Pharmaceutical business Segment.ttttttttttttt n6) Previous period/year figures have been recast/re-grouped to conform to the current period's presentation. n nOther Notes: n n1) In excel utility (XBRL) we are unable to find sub-heading as exchange fluctuation (gain/loss) under expenses head hence we have mentioned it under the heading other expense. n n2) Income Tax relating to items that will not be reclassified profit/loss Rs. 0.07 crore has been clubbed with principle item of other comprehensive income due to validation error. n Exchange fluctuation loss/ (gain), net -164600000.00 Other Expenses 1569400000.00